Amgen reports positive migraine study data for Aimovig

Amgen has announced new clinical trial data from a phase IIIb study assessing the safety and efficacy of Aimovig in the treatment of migraines.

Results from the LIBERTY study showed that patients with episodic migraine who had experienced two to four previous preventive treatment failures were able to achieve good results using Aimovig.

The study met its primary endpoint, with significantly more patients taking Aimovig experiencing at least a 50 percent reduction from baseline in their monthly migraine days compared to placebo.

All secondary endpoints were also achieved, including reduction of monthly migraine days, reduction in days needing acute medication, improvement in scores on the Migraine Physical Function Impact Diary tool, and strong response rates.

Dr Sean Harper, executive vice-president of research and development at Amgen, said: "We've purposely designed a clinical programme for Aimovig that examined a broad spectrum of migraine patients, ranging from those who have never tried a preventive treatment to patients who have tried and failed such treatments."

Aimovig is the only investigational fully human monoclonal antibody designed to selectively block the calcitonin gene-related peptide receptor, which is known to play a critical role in migraine activation.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.